MRD Detection Development Services for ALL

Measurable residual disease (MRD) serves as a diagnostic indicator for assessing the effectiveness of acute lymphocytic leukemia (ALL) treatment and guides subsequent therapeutic interventions. Since residual leukemia cells often fall below the detection thresholds of conventional morphological and cytogenetic assessments, precise and accurate MRD detection in ALL assumes paramount importance. Alfa Cytology offers comprehensive MRD detection services specifically tailored to ALL research. Our expertise lies in developing customized detection technologies to cater to your unique requirements.

Introduction to MRD in ALL

The monitoring of minimal residual disease (MRD) has now become an integral part of frontline therapy for the majority of pediatric ALL patients, as well as a significant number of adult ALL patients. Furthermore, the assessment of MRD following the induction phase of ALL treatment serves as a predictive measure for evaluating the efficacy of specific therapies. The diagnosis of MRD stands as the most influential prognostic factor, enabling risk stratification into various treatment categories, ranging from substantial treatment reduction to mild or intensive intensification strategies.

Fig. 1. Measurable residual disease assessment in acute lymphoblastic leukemia. (Logan, A.C., 2022)

Alfa Cytology provides comprehensive MRD detection development services for the management and therapy of ALL, including but not limited to the following.

Development of PCR-based Methods for MRD Detection in ALL

Based on our years of experience in PCR detection, we have developed and optimized the following PCR methods for ALL MRD detection and continue to develop new detection approaches. Given the prevalence of fusion genes in the majority of ALL cases, we have developed PCR technologies to assess MRD targeting these fusion genes. These fusion genes include BCR-ABL1, E2A-PBX1, KMT2A, and CRLF2 in B-ALL, as well as TAL1, TLX1, and TLX3 in T-ALL. We provide the following PCR technologies for MRD detection in ALL.

Additionally, we have developed third-generation PCR technology, digital droplet PCR (ddPCR), for MRD detection. With its higher sensitivity and improved detection limit, our offered ddPCR serves as a more sensitive MRD detection tool, particularly for Philadelphia-positive acute myeloid leukemia.

The ddPCR technology we provide offers greater accuracy compared to qPCR, as evidenced by the following:

• Each sample is partitioned into droplets, and each droplet is individually analyzed.
• Small changes in fluorescence intensity are easier to detect.
• The ratio between target DNA molecules and PCR reagents is significantly higher.

If you are planning to develop a new PCR method for ALL MRD detection, we offer PCR assay development services based on our existing PCR expertise to detect the genes of your interest.

Development of DNA Sequencing for MRD Detection in ALL

The NGS technology we have developed is a valuable tool for ALL MRD detection, used to detect the rearranged IG/TR DNA sequence. Our advantage is that the detected clone sequences can be retested and quantified in each subsequent sample. The NGS we have is used to monitor the consistency of gene rearrangements, providing a complete picture not only of residual leukemia but also of the complete repertoire of normal immune groups.

We are committed to standardizing NGS analysis and providing guidelines for data interpretation, reducing the complexity and significant costs of NGS-based MRD detection in ALL, and enhancing the availability of standardized protocols for MRD based on NGS in the laboratory.

Development of Flow Cytometry for MRD Detection in ALL

Advantages of Our Services

• Our team will work closely with you to design and optimize PCR assays that meet your specific objectives, ensuring accurate and sensitive MRD detection.
• Our team of experienced scientists and researchers specializes in the field of ALL.
• Our expertise ensures that we provide high-quality services tailored specifically to the needs of ALL research.
• We offer customized PCR method development services for MRD detection in ALL.
• We stay at the forefront of technological advancements in MRD detection.

Alfa Cytology provides advanced and comprehensive MRD detection services using state-of-the-art technologies. Our expertise in flow cytometry, PCR-based assays, and next-generation sequencing ensures accurate and sensitive MRD assessment, enabling better treatment decisions and improved patient outcomes. Contact us to learn more about our MRD detection services for ALL.